FindTrial
Sign In

Double-blind, parallel-group confirmatory study of AD-810N (zonisamide) in patients with Parkinson's disease

Double-blind, parallel-group confirmatory study of AD-810N (zonisamide) in patients with Parkinson's disease

Status
Unknown
Phases
Phase 3
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCT2080220368
Enrollment
Unknown
Registered
2007-03-28
Start date
2007-03-28
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Parkinson's disease

Interventions

investigational material(s) Generic name etc : AD-810N (zonisamide) INN of investigational material : Therapeutic category code : 116 Antiperkinsonism agents Dosage and Administration for Investigati

Sponsors

Dainippon Sumitomo Pharma Co., Ltd.
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: [Major inclusion criteria] - Patients with reduced response to L-DOPA - Age: >=20 and <75 (at the time of informed consent) [Major exclusion criteria] - Patients with Parkinson's syndrome other than Parkinson's disease - Patients with epilepsy - Patients with a history of treatment with zonisamide, or who have ever enrolled in other clinical trials related to AD-810N - Patients with a history of neuroleptic malignant syndrome

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Unified Parkinson's Disease Rating Scale (UPDRS)—

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026